glp-1 drug companies Shortages improve for Lilly's weight loss drugs, bumping sales forecast by $3bn GLP-1 Drugs from the Gray

Bias AA, Hiday RA, Kline MM

Green tea and soybeans are two examples of common foods whose bioactive components are also being studied [188]

Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity

The SELECT cardiovascular outcomes trial established that semaglutide reduces major adverse cardiovascular events by 20%, providing a strong clinical rationale for treatment that extends beyond weight management alone

Efficacy In the original phase 3 randomized trials for obesity, average weight reduction compared to placebo has ranged from 5.3 % to 17.8 % after 5672 weeks (Table 1), with improvements in several obesity-related risks and complications [[13], [14], [15]]

Tang ASP, Hsu JTY, Chong SKS et al (2025) Glucagon-like peptide-1 receptor agonist in myocardial infarction and atherosclerotic cardiovascular disease risk reduction: a comprehensive meta-analysis of number needed to treat, efficacy and safety